Press Release - Eurofins Acquires APAL
Eurofins Agro Testing is proud to announce the acquisition of Australian Precision Ag Laboratory (APAL) on 1st February 2022
The acquisition marks the entry of Eurofins Agro Testing into the Australian market. APAL will join the leading global network of Eurofins agro testing laboratories, operating in most geographies including New Zealand.
APAL is the leading provider of independent Farming and Agriculture Testing services in Australia and enjoyed tremendous growth over the years thanks to its dedication to independent, reliable and consistent service, backed by research and the latest scientific practice. Its culture of service and innovation is a perfect fit with Eurofins.
As the global leader in laboratory testing services, the partnership with Eurofins Agro Testing will allow APAL to continue to offer and further expand its highly reputable independent analytical services across the farming and agriculture markets. Eurofins APAL will continue to build on its client relationships and to expand its services nationally, and it will benefit from access and support from the global Eurofins network and synergies with the Eurofins agro testing laboratories and their global network of scientists committed to delivering good science, continuous innovation and impeccable service.
---
Notes to Editors:
APAL operation will hereinafter be trading as “Eurofins | APAL”.
All enquiries can be made to Eurofins | APAL on (08) 8332 0199
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research services. Eurofins is also one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, BioPharma Contract Development and Manufacturing, advanced material sciences and in the support of clinical studies. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 62,000 staff across a decentralised and entrepreneurial network of over 900 laboratories in 62 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.
Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).